Marathon Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $718K | Sell |
141,895
-7,950
| -5% | -$40.2K | 0.18% | 78 |
|
|
2025
Q1 | $793K | Buy |
149,845
+3,450
| +2% | +$18.3K | 0.21% | 69 |
|
|
2024
Q4 | $990K | Sell |
146,395
-35,450
| -19% | -$240K | 0.25% | 68 |
|
|
2024
Q3 | $1.2M | Buy |
181,845
+6,625
| +4% | +$43.7K | 0.29% | 62 |
|
|
2024
Q2 | $1.31M | Buy |
175,220
+2,675
| +2% | +$20.1K | 0.33% | 60 |
|
|
2024
Q1 | $1.72M | Buy |
172,545
+7,665
| +5% | +$76.4K | 0.41% | 54 |
|
|
2023
Q4 | $1.63M | Sell |
164,880
-5,735
| -3% | -$56.5K | 0.41% | 60 |
|
|
2023
Q3 | $1.31M | Buy |
+170,615
| New | +$1.31M | 0.33% | 65 |
|